A collaboration between researchers at New York University’s Grossman School of Medicine and Rocket Pharmaceuticals has produced preclinical evidence that gene replacement therapy successfully halts the progression of a potentially fatal heart disease. The study, led...
Jianyi “Jay” Zhang, M.D., Ph.D. Credit: UAB Severe heart attacks often progress to end-stage heart failure because the dearth of heart muscle cells diminishes pumping power of the heart’s left ventricle. The damaged heart, unable to repair itself,...
While FDA panelists supported Alnylam Pharmaceuticals’ medicine in transthyretin amyloidosis cardiomyopathy, they recommended a limited FDA approval that would severely restrict the med’s addressable population. (FDA) After Alnylam Pharmaceuticals faced...
